Sierra Oncology Inc (OQ:SRRA)

Business Focus: Bio Therapeutic Drugs

Recent Price for SRRA
USD 1.460 N/A (N/A)
NASDAQ Delayed 15 minutes
Mar 23 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 0.000 N/A N/A 76.24
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 0.000 0.0% 482,360  
Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 2150-885 Georgia St W
VANCOUVER BC V6C 3E8
Tel: N/A
Website: sierraoncology.staging.wpengine.com
IR: See website
Key People
Donald R. Parfet
Independent Chairman of the Board
Nicholas R. Glover
President, Chief Executive Officer, Director
Sukhi Jagpal
Chief Financial Officer
Wendy Chapman
Senior Vice President - Clinical Operations
Christian Hassig
Senior Vice President - Research
Chandra D. Lovejoy
Senior Vice President - Global Regulatory Affairs and Head of Quality
Barbara Klencke
Chief Development Officer
Angie J. You
Chief Business & Strategy Officer and Head of Commercial
 
Business Overview
Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company's lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company's SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.
Financial Overview
For the fiscal year ended 31 December 2016, Sierra Oncology Inc revenues was not reported. Net loss applicable to common stockholders decreased 89% to $47.9M. Lower net loss reflects Change in fair value of preferred stock decrease from $17.4M (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$31.47 to -$1.58.
Employees: 53 as of Dec 31, 2016
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Dec 31, 2016
EBITDA (TTM): -$47.88M as of Dec 31, 2016
Net annual income (TTM): -$47.87M as of Dec 31, 2016
Free cash flow (TTM): -$41.38M as of Dec 31, 2016
Net Debt Last Fiscal Year: N/A
Shares outstanding: 52,218,582 as of Feb 28, 2017
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization